Nuvectis Pharma Investor Relations Material
Latest events
Status Update
Nuvectis Pharma
Q1 2025
6 May, 2025
Q4 2024
25 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Nuvectis Pharma Inc
Access all reports
Nuvectis Pharma, Inc. is a biopharmaceutical company specializing in the development of precision medicines aimed at addressing significant unmet medical needs in oncology. The company's development pipeline includes two key clinical-stage drug candidates: NXP800 and NXP900. The company is headquartered in Fort Lee, New Jersey, and its shares are listed on the NASDAQ.
Latest articles
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
Ticker symbol
NVCT
Country
🇺🇸 United States